Brii Biosciences (2137) Corporate presentation summary

Mission and focus

• Aims to address public health challenges through scientific innovation and patient insights.

• Focuses on novel treatment options for HBV cure and infectious diseases with high unmet needs.

• Recognizes significant social stigma and limited treatment options for patients.

Leadership and governance

• Executive team includes experienced leaders from major pharmaceutical and biotech firms.

• Board and advisors feature industry veterans and scientific experts.

HBV cure program

• China represents a large HBV market with ~71M infected and high unmet need for new therapies.

• Current standard of care has low cure rates and requires lifelong treatment.

• Pipeline includes BRII-179 (therapeutic vaccine), elebsiran (siRNA), and tobevibart (bnAb), each with unique mechanisms.

• Multiple Phase 2 studies (ENSURE, ENRICH, ENHANCE) are ongoing to optimize combination regimens.

• BRII-179 immune profiling identifies patients more likely to achieve functional cure.

• Recent data show higher HBsAg loss rates with combination therapies, especially in BRII-179 responders.

• Key data readouts expected in 2025-2026.